ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Therefore, the frequent and serious multi-TKI resistance has been a major obstacle in the clinical treatment of CML, and novel agents or alternative strategies to overcome BCR-ABL mutations are still badly needed.